Feeds:
Posts
Comments

Not much is known about older adult’s use of prescription and over-the-counter medication. 800px-Pill_box_with_pillsThis is so, despite concerns about drug safety. The objective of this study, therefore, was to estimate the prevalence and patterns of medication use among older adults to determine the risk for major drug-drug interactions.

Three thousand five people aged 57 to 85 years, who lived in communities, were investigated by using in-home interviews and medication logs. The study was conducted between June 2005 and March 2006.

The results estimated that at least 91% of older adults regularly used at least 1 medication, of which the most common was prescription medication. The prevalence of prescription medication use was most common among the oldest people. Nearly one-half of older adults used at least one over-the-counter medication or dietary supplement. The data also show that women were more likely to use prescription medications than men.  Two groups of people were more likely to use medication: those in poorer health, and those who were better educated.  The most commonly used prescription or over-the-counter medications were cardiovascular agents, including antihyperlipidemics and anticoagulants. The most commonly used dietary supplements were multivitamins, vitamins and minerals.

COMMENT
♣    This study found that more than half of older adults used 5 or more prescription medications, over-the-counter medications or dietary supplements.
♣    Nearly 1 in 25 older people are at risk for a drug-drug interaction.
♣    Half of the people in this high-risk group were using nonprescription medications.
♣    This finding has major clinical implications, because many doctors are unaware of their patient’s non-prescription medication use, and a recent report estimated that in the US, adults older than 65 make more than 175,000 emergency department visits per year due to adverse drug events.

To read this study in its entirety, go to JAMA December 24/31, 2008, Vol 300 No. 24, pp. 2867-2878
-–Cynthia Haggard is a medical writer who lives in Washington DC.  She owns her own business, Clarifying Concepts, which provides technical writing, writing for the public, and regulatory affairs services.  To see more, please go to clarifyingconcepts. (c) 2009 All rights reserved.

Children who have attention-deficit/hyperactivity disorder (ADHD) often have developmental coordination disorder (DCD).  DCD is a condition in which children have noticeable problems in moving, walking and manipulating objects without a medical problem like cerebral palsy.  DCD occurs in approximately 5% to 7% of school-age children and about 30% to 50% of children with ADHD also have DCD.   The coexistence of ADHD with DCD leads to the greater likelihood of psychiatric and substance abuse problemsdopamine later in life.

The authors investigated the possibility of a shared etiology between ADHD and DCD by examining data from the Dutch sample of the International Multicenter ADHD Genetics study. The data came from 275 children with ADHD and their affected or unaffected sibling, as well as 146 unrelated children who were used as controls.

Results show that the ADHD-affected children were significantly more likely to have DCD than their unaffected siblings. In turn, the unaffected siblings of ADHD-affected children were also significantly more likely to have DCD than the control subjects. The data also suggest that the co-occurrence of ADHD and DCD may mark a distinct subtype of ADHD, rather than a more severe form of the disorder.

COMMENT
♣    The role of the dopamine system in the progress of ADHD is well known.
♣    It is also known that genetic variations in dopaminergic genes contribute to ADHD risk.
♣    Several studies also point to the role of the dopaminergic system in motor control.
♣    Since animal studies have found an association between locomotor behavior and polymorphisms of the dopadecarboxylase gene – which in involved in the synthesis of serotonin and dopamine – it seems that more research into the genetics of the dopamine pathway might help to find the underlying mechanism that is responsible for both ADHD and DCD.

To read this study in its entirety, go to J. AM. ACAD. CHILD ADOLESC. PSYCHIATRY, 48:1, January 2009, pp. 25-34.

-–Cynthia Haggard is a medical writer who lives in Washington DC.  She owns her own business, Clarifying Concepts, which provides technical writing, writing for the public, and regulatory affairs services.  To see more, please go to clarifyingconcepts. (c) 2009 All rights reserved.

Wheezing is common in preschool children between the ages of 10 months and 6 years. It is a sound associated with breathing that occurs when there is some kind of blockage596px-Inhaler of the respiratory system. When wheezing attacks are caused by upper respiratory viral infections, the standard treatment is a short course of oral prednisolone, but there is conflicting evidence regarding its effectiveness for children in this age group.

The authors conducted a randomized double-blind placebo-controlled trial to assess the effectiveness of oral prednisolone. Outcomes were measured in terms of the length of hospital stay, the score on the Preschool Respiratory Assessment Measure, albuterol use, and a 7-day symptom score.

Results showed that there were not significant differences on any of the outcome measures between using prednisolone and using a placebo.

COMMENT
♣    Prednisolone is a corticosteroid drug that has anti-inflammatory properties.  This study’s findings conflict with those of other studies that report a beneficial effect of corticosteroids in the treatment of wheezing.
♣    The authors believe that the main reason why their study’s findings differ is because the children in this study did not present with the classic symptoms of allergy-induced asthma, which is responsive to a short course of oral corticosteroids.
♣    The authors of this study did not analyze the viral infections that caused these children to wheeze, so it is not known whether they suffered from one type of virus or several.
♣    Since a recent study (Jartti et al. 2006) has raised the possibility that children respond to corticosteroid treatment differently as a function of the type of virus they are infected with, it seems important to pursue this line of research by first identifying the viruses, and then designing experiments to test various kinds of treatment.

To read this study in its entirety, go to N ENGL J MED 360:4, January 22, 2009, pp. 329-338

-–Cynthia Haggard is a medical writer who lives in Washington DC.  She owns her own business, Clarifying Concepts, which provides technical writing, writing for the public, and regulatory affairs services.  To see more, please go to clarifyingconcepts. (c) 2009 All rights reserved.

There is emerging evidence for clinical and biological links between autism/pervasive developmental disorder (PDD) and schizophrenia, with particular attention to childhood-onset schizophrenia (COS). AutismAutism-stacking-cans_edit is a brain development disorder characterized by impaired social interaction and communication, and by restricted and repetitive behavior. These signs all begin before a child is three years old. PDD is a broader category that subsumes autism. Symptoms of PDD may include communication problems such as:
♣    Difficulty using and understanding language
♣    Difficulty relating to people, objects, and events; for example, lack of eye contact or pointing behavior
♣    Unusual play with toys and other objects
♣    Difficulty with changes in routine or familiar surroundings
♣    Repetitive body movements or behavior patterns

By contrast, a person diagnosed with schizophrenia may suffer from:
♣    Auditory hallucinations
♣    Delusions
♣    Disorganized and unusual thinking and speech

Childhood-onset schizophrenia is defined as onset of psychosis before 13 years and is a rare and severe form of schizophrenia. Onset is usually after age 7 years, and prognosis is poor.

The authors took clinical, demographic, and brain developmental data from the National Institute of Mental Health (and other) COS studies and reviewed family, imaging, and genetic data from studies of autism, PDD, and schizophrenia. In the two large studies that have examined these phenomena systematically, COS is preceded by and comorbid with PDD in 30% to 50% of cases. Other studies of children with early-onset schizophrenia have found evidence of pre-existing or co-existing developmental abnormalities primarily for communication, motor abnormalities, and/or social relatedness. For example, an early article from the UCLA COS study found that 39% of a sample of 33 patients had symptoms of autism years before onset of schizophrenia.

Epidemiological and family studies also find association between the disorders. In the current NIMH study to date, 263 family members were evaluated. Evidence from this study shows that the average Autism_awareness_ribbon-20051114Autism Screening Questionnaire score was higher among unaffected sibling of children with comorbid PDD/COS than among unaffected siblings of COS patients without PDD, as consistent with previous articles, implying that PDD symptoms are heritable and may serve as trait markers even in unaffected individuals.

Another interesting finding is that both disorders show evidence of accelerated trajectories of anatomic brain development at ages near disorder onset. Most researchers agree increased head size/total brain volume seen in the first 3 years of age is a marker for autism. This brain overgrowth that precedes or coincides with the appearance of signs and symptoms of autism suggests that it may be a fundamental aspect of the pathological process. In COS, there is exaggeration of the brain maturation processes of childhood and early adolescence.

Lastly, a growing number of risk genes and rare small chromosomal variants (microdeletions or duplications) are shared by schizophrenia and autism.

COMMENT:
Despite the fact that symptoms associated with PDD (which includes autism) are not like those associated with COS, there are new data to indicate that, autism and schizophrenia are more likely to be seen in the same patients and families: Large epidemiological and patient-population data show familial schizophrenia-like psychosis to be a risk factor for (narrowly defined) autism.
♣    Why are the links between these illnesses not seen by the treating clinician?
♣    One reason is that the children who typically have these conditions present with a variety of symptoms which dilutes the effects in smaller samples.
♣    The other reason is that autism and schizophrenia are mutually exclusive under the current diagnostic hierarchy. This means that if a person develops autism as a young child, they may be unlikely to receive a diagnosis of schizophrenia later on, even if new symptoms emerge.
♣    To address these issues, the training of psychiatrists who treat adults with this spectrum of disorders needs to include the diagnosis of adults with autism and autism spectrum/PDD to discriminate the milder forms of autism spectrum and schizophrenia spectrum disorder for future family studies.
♣    Lastly, a meticulous study of genetic and syndromal heterogeneity is needed to form a foundation for future clinical neuroscience.

To read this study in its entirety, go to J Am Acad Child Acolesc Psychiatry, 48:1, January 2009, pp. 10-18.

-–Cynthia Haggard is a medical writer who lives in Washington DC.  She owns her own business, Clarifying Concepts, which provides technical writing, writing for the public, and regulatory affairs services.  To see more, please go to clarifyingconcepts. (c) 2009 All rights reserved.

Volumetric abnormalities of basal ganglia PutamenCaudateNhave been associated with attention deficit hyperactivity disorder (ADHD) especially in boys.  ADHD is a prevalent neuropsychiatric syndrome characterized by excessive difficulty with focusing attention, sitting still and controlling impulses. Before the era of neuroimaging, neurologists reported motor impairments and cognitive anomalies that implicated the frontal lobe. Among these subcortical regions, the basal ganglia have been particularly emphasized because they are important for selecting appropriate goal-directed behavior.

The authors examined the effects of ADHD, sex and their interaction on the shapes and sizes of three basal ganglia structures (caudate, putamen, globus pallidus) by using large deformation diffeomorphic metric mapping (LDDMM). LDDMM mappings from 35 typically developing children were used to generate basal ganglia templates.  The basal ganglia (caudate, putamen, globus pallidus) were manually delineated on magnetic resonance imaging from 66 typically developing children (35 boys) and 47 children (27 boys) with ADHD. Shape variations of each structure relative to the template were modeled for each subject as a random field using Laplace-Beltrami basis function in the template coordinates. Linear regression was used to examine group differences in volumes and shapes of the basal ganglia.

Boys with ADHD showed significantly small basal ganglia volumes compared with typically developing boys, and LDDMM revealed the groups differed to a large degree in the shapes of the various structures that make up the basal ganglia. Volume compression was seen bilaterally in the caudate head and body, the anterior putamen, the left anterior globus pallidus, and the right ventral putamen. Volume expansion was most pronounced in the posterior putamen. No volume or shape differences were revealed in girls with ADHD.

The shape compression pattern of basal ganglia in boys with ADHD suggests that ADHD-associated deviations from typical brain development involved multiple frontal-subcortical control loops, including circuits with premotor, oculomotor, and prefrontal cortices. Further investigations employing brain-behavior analyses will help to discern the task-dependent contributions of these circuits to impaired response control that is characteristic of ADHD.

COMMENT:
The finding that girls with ADHD did not exhibit differences in basal ganglia volume and shape when compared with normally developing girls suggests several possibilities:
♣    The underlying neuropathophysiologic processes in boys and girls with ADHD is fundamentally different.
♣    The core neuroanatomic abnormalities for girls with ADHD are to be found elsewhere, but not in the basal ganglia.
♣    The seeming correlation between smaller basal ganglia volumes together with shape compression and ADHD in boys may mask a subtler problem, suggesting that a good research path would be to do an in-depth comparison of the brains of girls with ADHD and normally-developing girls.

To read this study in its entirety, go to Am J Psychiatry 166:1 January 2009, pp. 74-82.
-–Cynthia Haggard is a medical writer and teacher who lives in Washington DC.  She owns her own business, Clarifying Concepts, which provides technical writing, writing for the public, teaching, and regulatory affairs services.  To see more, please go to clarifyingconcepts. (c) 2009 All rights reserved.

Wasting affects approximately 10% of the world’s children younger than 5 years, and is an important contributor to the population-attributable risk of child mortality and overall burden of disease. In Niger,niger a country of 14 million people, household food production is linked to rain fed agriculture. Staple crops such as millet and sorghum are harvested once per year from September to October.

Each year the decrease in food quantity and quality experienced in the months preceding the harvest (August to October) is associated with an increase in wasting among children younger than 5 years.

The authors assessed whether Ready-to-Use Therapeutic Food (RUTF) would prevent declines in individual weight-for-height and reduce the incidence of wasting in children aged 6 to 60 months over a period of 8 months. These foods are energy-dense, micronutrient-enriched pastes with a nutritional profile similar to the traditional F-100 milk-based diet used in inpatient therapeutic feeding programs and often made up of peanuts, oil, sugar and milk powder.

Between August and October 2006, half of the villages in the study received a monthly distribution of 1 sachet per day of RUTF (92g [500 kcal/d]; Plumpy nut; Nutriset, Malaunay for their children under five years.

During monthly follow-up visits, measurements were taken of children’s height and weight. The primary outcome measures were individual WHZ score according to the World Health Organization Child Growth Standards, and wasting (WHZ < -2. Secondary measures included severe wasting (WHZ < -3), height-for-age z score (HAZ) according to the World Health Organization Child Growth Standards, stunting (HAZ < -2), severe stunting (HAZ < -3), mortality, and prevalence of malaria, diarrhea, and respiratory tract infection.

The intervention resulted in a 36% (95% CI, 17% to 50%; P < .001) reduction in the incidence of wasting and a 58% (95% CI, 43% to 68%; P < .001) reduction in the incidence of severe wasting. There was no observed effect of the intervention on the prevalence of malaria, diarrhea or respiratory tract infection.

Possible problems with this study :
♣    There was a limited effect of RUTF on stunting, possible due to the short duration of supplementation.

♣    The intervention did not have a significant effect on diarrhea and respiratory tract infection.

♣    The authors were unable to measure dietary intakes at recruitment or during the intervention.

♣    Although the authors found no evidence for this, there was a concern that the packets of high-energy food might be resold in local markets.

To read this study in its entirety, go to JAMA, January 21 2009–Vol 301. No.3, pp. 277-285.

-–Cynthia Haggard is a medical writer and teacher who lives in Washington DC.  She owns her own business, Clarifying Concepts, which provides technical writing, writing for the public, teaching, and regulatory affairs services.  To see more, please go to clarifyingconcepts. (c) 2009 All rights reserved.

NOTE: This is Part 5 of a 5-part piece. Click here for Part 1.  Click here for Part 2.  Click here for Part 3.  Click here for Part 4.

Today I’m going to muse about what could happen to suddenly cause medical writing to dry up.  No one likes to think about negative things like business drying up. But on the other hand, people who work for themselves know that the worst possible thing that can happen is for the business to be made irrelevant by a trend that the CEO failed to notice.  So today, we are going to explore two possible trends that could cause medical writing to dry up.

The first trend is the decrease in the number of senior citizens.  When the current population of baby boomers passes on, there will not be a need for the huge number of medications related to chronic illness such as diabetes, heart disease and stroke.  This relative lack of need for medication could translate into a dearth of work for all the support services needed to inform the public, including medical writing. At the moment however, we are seeing an upswing in the number of people over the age of 50, so this trend is one that is not going to affect us for some time.  People who are now approaching retirement age could be around for the next 30 or 40 years, making it a good time to get into a medical writing career.  But at some point in the future, the pendulum will swing back again, and then times could be lean.

Another possible scenario – as mentioned last week – is that medical writers may go out of existence due to the fact that young people read less and less.  Therefore, information may have to be packaged in a different way, perhaps by using computer games, or at any rate something more visual and interactive.  The trouble is that the skill set needed to create information that is visual and interactive is very different form the skill set needed to write.  If this transformation really took hold, medical writers could be out of a job.

Of the two trends, the second one seems more serious to me.  What can we do to get our kids to read more?

Asklepios image: wikipedia

Quill pen image: wikipedia

–Cynthia Haggard is a medical writer and editor and lives in Washington DC.  She recently opened her own business, Clarifying Concepts, which provides grant writing, speechwriting, technical writing, writing for the public and regulatory affairs services.  To see more, please go to clarifyingconcepts. (c) 2008 All rights reserved.

This course is designed for members of the public, health-care professionals, and parents of special needs children who need to read medical articles, but struggle with the statistics and medical terminology.

Welcome to Demystifying Science: A guide for dealing with medical jargon and other blocks to understanding science. In this fast-paced two-hour class, you will learn:
•    How to decode medical terms,
•    How to interpret intermediate-level statistics
•    How to take a journal article and turn it into a report

At the April 9th class, we will discuss: Autism Spectrum Disorders and Childhood-Onset Schizophrenia: Clinical and Biological Contributions to a Relation Revisited, J. Am. Acad. Child Adolesc. Psychiatry, 48:1, January 2009.

WHERE: Apolline, 1330 New Hampshire Ave NW, at 20th & New Hampshire, near Dupont Circle metro stop
WHEN: Thursday April 9, 2009 from 6:30-8:30 pm
COST: $50/person. **No walk-ins please**
REGISTER: Point your browser to: http://clarifyingconcepts.com/Courses.html

–Cynthia Haggard is a medical writer and teacher who lives in Washington DC.  She owns her own business, Clarifying Concepts, which provides technical writing, writing for the public, teaching, and regulatory affairs services.  To see more, please go to clarifyingconcepts. (c) 2009 All rights reserved.

NOTE: This is Part 4 of a 5-part piece.  Part 5 will appear next week.  Click here for Part 1.  Click her for Part 2.  Click here for Part 3.

It is sometimes fun to sit back and imagine what will happen in the future.  That is what I’m going to do today.  What does the future look like for medical writing? Two possible scenarios come to mind.

When I think of the millions of baby-boomers who are now aging, it is easy to think that there is going to be a greater need for medical writing.  As writing is a very portable career, the increasing sophistication in technology and the need to be green means that more people will be able to work from home. This is good news for people who don’t like working from other people’s offices.

So far, we have a rosy picture. One fly in the ointment, however, is the fact that young people do not read much.  So the challenge is going to be how to convey medical information in a non-verbal form.  Recently I read of a computer game being used in spiritual practice.  Is it possible that computer games could be the venue for conveying medical information rather than the written word? Maybe all of us who now write will have to think about creating games, just as we now set up websites and blog.  Who knows? Instead of worrying about my daily blog or website, in ten or twenty years I might be spending my old age creating games about psychotropic drugs!

If you wish to learn more about the American Medical Writers Association, a good plan would be to go to a local event. The American Medical Writers Association (AMWA) Mid-Atlantic Chapter (MAC) is holding its annual conference and dinner in Washington, DC on Saturday, June 21, 2008. The conference will feature several courses on editing and writing geared towards medical, science, and other research-focused writers. The deadline for conference registration is fast approaching (May 16th) so be sure to contact AMWA-MAC if you are interested. For more information about the conference, download the conference brochure or contact Amy Hereford, the Chapter Conference Coordinator.

Asklepios image: wikipedia

Quill pen image: wikipedia

–Cynthia Haggard is a medical writer and teacher who lives in Washington DC.  She owns her own business, Clarifying Concepts, which provides technical writing, writing for the public, teaching, and regulatory affairs services.  To see more, please go to clarifyingconcepts. (c) 2009 All rights reserved.

NOTE: This is Part 3 of a 5-part piece. Part 4 will appear next week.  Click here for Part 1.  Click here for Part 2.

Many members of the American Medical Writers Association (AMWA) work for pharmaceutical companies.  Their job is to research, write, edit and compile documents to be submitted to the Food and Drug Administration (FDA) on behalf of the pharmaceutical company they work for.  This puts the medical writer in a very difficult position.  On the one hand, they are being paid by a pharmaceutical company.  On the other hand, they are ethically obliged to provide accurate scientific information to the FDA.  While many people who work in pharmaceutical companies try hard to be honest – for example, I know of one company that stopped its drug development cold when it became evident that it had no more effect on curing the problem that a placebo – there is pressure to make the drug in question sound better than might be strictly warranted by the facts.

Some pharmaceutical companies are developing ever more subtle and clever strategies to convince the public that their drug is really the best choice.  For example, the Journal of The American Medical Association (JAMA) recently reported the alleged misuse of medical writing resources by Merck in publications about rofecoxib (Vioxx), specifically that a medical writer or writers had written up the material about Vioxx for Merck, without receiving any public recognition for their role in putting this material out for public consumption.  Instead, Merck had allegedly paid some famous clinicians and researchers to put their names on these articles they did not write.  This practice is known as ghostwriting.

AMWA responded with a letter to the editor of the New York Times, published April 20, in which it advocated for the full disclosure of potential conflicts of interest:  “Transparent disclosure of the roles of all contributors avoids ghostwriting and allows readers to evaluate the credibility of research reports.”

For more information about the accusations against Merck, go to jama.ama-assn.org.  For AMWA’s response, go to  www.nytimes.com/2008/04/20/opinion.

For more information about ghostwriting, go to an article I wrote three years ago for the Mid-Atlantic Chapter website of AMWA.

Asklepios image: wikipedia

Quill pen image: wikipedia

–Cynthia Haggard is a medical writer and teacher who lives in Washington DC.  She owns her own business, Clarifying Concepts, which provides technical writing, writing for the public, teaching, and regulatory affairs services.  To see more, please go to clarifyingconcepts. (c) 2009 All rights reserved.

Older Posts »